Plasma extracellular microRNAs are related to AIDS/cerebral toxoplasmosis co-infection.

Publisher: Wiley Country of Publication: England NLM ID: 7910948 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-3024 (Electronic) Linking ISSN: 01419838 NLM ISO Abbreviation: Parasite Immunol Subsets: MEDLINE

Original Publication: Oxford, Wiley

Toxoplasma*/physiology; HIV Infections/*blood ; MicroRNAs/*blood ; Toxoplasmosis, Cerebral/*blood; Biomarkers/blood ; Coinfection ; Enzyme-Linked Immunosorbent Assay ; Female ; Gene Expression ; HIV Infections/complications ; Humans ; Male ; MicroRNAs/genetics ; Real-Time Polymerase Chain Reaction ; Toxoplasmosis, Cerebral/complications

This study investigated the potential of five miRNA candidates for cerebral toxoplasmosis/HIV co-infection (CT/HIV) biomarkers. miR-155-5p, miR-146a-5p, miR-21-5p, miR-125b-5p and miR-29c-3p were tested in 79 plasma divided into groups: 32 CT/HIV patients; 27 individuals with asymptomatic toxoplasmosis (AT); and 20 individuals seronegative for toxoplasmosis (NC). From each was collected peripheral blood/EDTA for laboratory diagnosis. Blood cells for DNA extractions (molecular diagnosis), plasma for RNA extractions (gene expression) and ELISA (serological diagnosis). miRNA expression was performed by qPCR, and values were expressed in Relative Quantification (RQ). Among the five miRNAs, miR-21-5p and miR-146a-5p were up-expressed in CT/HIV group when compared with AT and NC groups. RQ means for miR-21-5p and miR-146a-5p in CT/HIV group were 3.829 and 2.500, while in AT group, were 1.815 and 1.661, respectively. Differences between 3 groups were statistically significant (Kruskal-Wallis ANOVA test), as well as CT/HIV and AT groups (Mann-Whitney test). Plasma of CT/HIV and AT groups expressed similar levels of miR-29c-3p, miR-155-5p and miR-125b-5p. As NC group was different of CT/HIV and AT groups, differences between three groups were statistically significant (Kruskal-Wallis ANOVA test). No difference was shown between CT/HIV and AT groups (Mann-Whitney test). These results suggest the host miRNAs modulation by Toxoplasma gondii.
(© 2020 John Wiley & Sons Ltd.)

Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004;363:1965-1976.
Pereira-Chioccola VL, Vidal JE, Su C Toxoplasma gondii infection and cerebral toxoplasmosis in HIV-infected patients. Future Microbiol. 2009;4:1363-1379.
Dubey JP. The history of Toxoplasma gondii - the first 100 years. J Eukaryot Microbiol. 2008;55:467-475.
Saadatnia G, Golkar M. A review on human toxoplasmosis. Scand J Infect Dis. 2012;44:805-814.
Butler NJ, Furtado JM, Winthrop KL, Smith JR. Ocular toxoplasmosis II: clinical features, pathology and management. Clin Exp Ophthalmol. 2013;41:95-108.
Luft BJ, Chua A. Central nervous system toxoplasmosis in HIV: pathogenesis, diagnosis, and therapy. Curr Infect Dis. 2000;2:358-362.
Vidal JE, Oliveira AC. AIDS-related cerebral toxoplasmosis in São Paulo State, Brazil: marked improvements in the highly active antiretroviral therapy-era but the challenges continue. Braz J Infect Dis. 2013;17:379-380.
Vidal JE. HIV-related cerebral toxoplasmosis revisited: current concepts and controversies of an old disease. J Int Assoc Provid AIDS Care. 2019;18:2325958219867315.
Carruthers VB, Suzuki Y. Effects of Toxoplasma gondii infection on the brain. Schizophr Bull. 2007;33:745-751.
Sarciron ME, Gherardi A. Cytokines involved in toxoplasmic encephalitis. Scand J Immunol. 2000;52:534-543.
Weiss LM, Kim K. The development in biology of bradyzoites of Toxoplasma gondii. Front Biosci. 2000;5:391-405.
Gazzinelli RT, Denkers EY, Sher A. Host resistance to Toxoplasma gondii: model for studying the selective induction of cell-mediated immunity by intracellular parasites. Infect Agents Dis. 1993;2:139-149.
Meira CS, Pereira-Chioccola VL, Vidal JE, et al. Cerebral and ocular toxoplasmosis related with IFN-γ, TNF-α, and IL-10 levels. Front Microbiol. 2014;5:00492. eCollection.
Meira CDS, Pereira-Chioccola VL, Vidal JE, et al. Evolution of cytokine profile during the treatment of cerebral toxoplasmosis in HIV-infected patients. J Immunol Methods. 2015;426:14-18.
Winter J, Jung S, Keller S, et al. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009;11:228-234.
Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215-233.
Chen XI, Liang H, Zhang J, Zen KE, Zhang C-Y. Horizontal transfer of microRNAs: molecular mechanisms and clinical applications. Protein Cell. 2012;3:28-37.
O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol. 2010;10:111-122.
Kanno Y, Vahedi G, Hirahara K, Singleton K, O'Shea JJ. Transcriptional and epigenetic control of T helper cell specification: molecular mechanisms underlying commitment and plasticity. Annu Rev Immunol. 2012;30:707-731.
Manzano-Román R, Siles-Lucas M. MicroRNAs in parasitic diseases: potential for diagnosis and targeting. Mol Biochem Parasitol. 2012;186:81-86.
Cai Y, Shen J. Modulation of host immune responses to Toxoplasma gondii by microRNAs. Parasite Immunol. 2017;39: https://doi.org/10.1111/pim.
Cannella D, Brenier-Pinchart M-P, Braun L, et al. miR-146a and miR-155 delineate a microRNA fingerprint associated with Toxoplasma persistence in the host brain. Cell Rep. 2014;6:928-937.
Rodriguez A, Vigorito E, Clare S, et al. Requirement of bic/microRNA-155 for normal immune function. Science. 2007;316:608-611.
Oertli M, Engler DB, Kohler E, et al. MicroRNA-155 is essential for the T cell-mediated control of Helicobacter pylori infection and for the induction of chronic gastritis and colitis. J Immunol. 2011;187:3578-3586.
Thai T-H, Calado DP, Casola S, et al. Regulation of the germinal center response by microRNA-155. Science. 2007;316:604-608.
Amado T, Schmolka N, Metwally H, et al. Cross-regulation between cytokine and microRNA pathways in T cells. Eur J Immunol. 2015;45:1584-1595.
Escobar T, Kanellopoulou C, Kugler D, et al. miR-155 activates cytokine gene expression in Th17 cells by regulating the DNA binding protein Jarid2 to relieve polycomb mediated repression. Immunity. 2014;40:865-879.
Yang L, Boldin MP, Yu Y, et al. miR-146a controls the resolution of T cell responses in mice. J Exp Med. 2012;209:1655-1670.
Lu L-F, Boldin MP, Chaudhry A, et al. Function of mir-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell. 2010;142:914-929.
Li L, Wang X, Li W, et al. mir-21 modulates prostaglandin signaling and promotes gastric tumorigenesis by targeting 15-PGDH. Bioch Bioph Res Comm. 2018;495:928-934.
Lu TX, Hartner J, Lim E-J, et al. MicroRNA-21 limits in vivo immune response mediated activation of the IL-12/IFN-gamma pathway, Th1 polarization, and the severity of delayed-type hypersensitivity. J Immunol. 2011;187:3362-3373.
Wang Z, Cai Q, Jiang Z, et al. Prognostic role of microrna-21 in gastric cancer: a meta-analysis. Med Sci Monit. 2014;20:1668-1674.
Cong W, Zhang XX, et al. Global mirna expression profiling of domestic cat livers following acute Toxoplasma gondii infection. Oncotarget. 2017;8:25599-25611.
Wei B, Pei G. Micrornas: critical regulators in Th17 cells and players in diseases. Cell Mol Immunol. 2010;7:175-181.
Li S, Yang J, Wang L, Du F, Zhao J, Fang R. Expression profile of micrornas in porcine alveolar macrophages after Toxoplasma gondii infection. Parasit Vectors. 2019;12:65.
Jiang J, Yu C, Chen M, Zhang H, Tian SE, Sun C. Reduction of mir-29c enhances pancreatic cancer cell migration and stem cell-like phenotype. Oncotarget. 2015;6:2767-2778.
Xia X, Teotia P, Ahmad I. Mir-29c regulates neurogliogenesis in the mammalian retina through REST. Devel Biol. 2019;450:90-100.
Camilo LM, Pereira-Chioccola VL, Gava R, et al. Molecular diagnosis of symptomatic toxoplasmosis: a 9-year retrospective and prospective study in a referral laboratory in São Paulo, Brazil. Braz J Infect Dis. 2017;21:638-647.
Meira CS, Costa-Silva TA, Vidal JE, Ferreira IMR, Hiramoto RM, Pereira-Chioccola VL. Use of the serum reactivity against Toxoplasma gondii excreted-secreted antigens in cerebral toxoplasmosis diagnosis in human immunodeficiency virus-infected patients. J Med Microbiol. 2008;57:845-850.
da Costa-Silva TA, da Silva Meira C, Frazzatti-Gallina N, Pereira-Chioccola VL Toxoplasma gondii antigens: recovery analysis of tachyzoites cultivated in Vero cell maintained in serum free medium. Exp Parasitol. 2012;130:463-469.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408.
Dai R, Ahmed SA. Sexual dimorphism of miRNA expression: a new perspective in understanding the sex bias of autoimmune diseases. Ther Clin Risk Manag. 2014;10:151-163.
Yuan Y, Liu L, Chen HU, et al. Comprehensive characterization of molecular differences in cancer between male and female patients. Cancer Cell. 2016;29:711-722.
Hannum C, Freed J, Tarr G, Kappler J, Marrack P. Biochemistry and distribution of the T cell receptor. Immunol Rev. 1984;81:161-176.
Schulze-Luehrmann J, Ghosh S. Antigen-receptor signaling to nuclear factor kappa B. Immunity. 2006;25:701-715.
Sheedy FJ. Turning 21: induction of miR-21 as a key switch in the inflammatory response. Front Immunol. 2015;6:19.
Saba R, Sorensen DL, Booth SA. Microrna-146a: a dominant, negative regulator of the innate immune response. Front Immunol. 2014;5:578.
Slota JA, Booth SA. Micrornas in neuroinflammation: implications in disease pathogenesis, biomarker discovery and therapeutic applications. Non-coding RNA. 2019;5:35.
Meira-Strejevitch CS, Pereira IS, Hippólito DDC, et al. Ocular toxoplasmosis associated with up-regulation of miR-155-5p/miR-29c-3p and down-regulation of miR-21-5p/miR-125-5p. Cytokines. 2020;127. https://doi.org/10.1016/j.cyto.2020.154990.
Maia MM, Meira-Strejevitch CS, Pereira-Chioccola VL, et al. Evaluation of gene expression levels for cytokines in ocular toxoplasmosis. Parasite Immunol. 2017;3:12462.
Correia CN, Nalpas NC, McLoughlin KE, et al. Circulating microRNAs as potential biomarkers of infectious disease. Front Immunol. 2017;16:118.

Keywords: cerebral toxoplasmosis; cytokine regulation; extracellular miRNA; gene expression

0 (Biomarkers)
0 (MicroRNAs)

Date Created: 20200117 Date Completed: 20200825 Latest Revision: 20200825

20231215

10.1111/pim.12696

31945196